Background/Aims: As the optimal stereotactic body radiation therapy (SBRT) modality for hepatocellular carcinoma (HCC) has not been confirmed, we aimed herein to provide a practical guideline by our retrospective review. Methods: Thirty-nine patients with primary HCC who underwent liver SBRT via 3 modalities (helical tomotherapy [HT]: 22, volumetric modulated arc therapy [VMAT]: 13, Cyberknife: 4) at our institution between July 2014 and July 2015 were included. Modalities were compared with regard to dose conformity index (CI), homogeneity index (HI), clinical results, and patient compliance. Results: VMAT SBRT had favorable conformity (CI: 0.7±0.2), homogeneity (HI: 1.1±0.0), and shortest treatment time (100.2±26.1 seconds). HT SBRT yielded good dosimetric outcomes, especially in conformity (CI: 1.0±0.2). Although the Cyberknife SBRT synchrony system allowed real-time tumor targeting, the treatment time was longest (3,015.0±447.3 seconds), invasive pre-treatment procedures were required, and the HI (1.3±0.0) was lowest. Conclusions: All 3 modalities yielded competent dosimetric planning parameters. VMAT SBRT was most appropriate for tumors with residual lipiodol or patients with poor conditions. HT SBRT is available for multiple or irregular targets. Cyberknife SBRT is recommended for carefully selected patients and tumors indicated for sono-guided fiducial insertion. (J Liver Cancer 2017;17:45-53)
INTRODUCTION
Resection, ablation, and liver transplantation are the available curative options for hepatocellular carcinoma (HCC), according to many clinical practice guidelines. However, only 10-20% of patients with HCC have resectable tumors 1, 2 ; here, potentially curative options such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), transarterial chemoinfusion (TACI), or radiotherapy should be consid-
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ered for locoregional tumor control rather than other systemic therapies or supportive care. In particular, radiotherapy is one of effective locoregional therapies. Although radiotherapy is not a standard treatment in the Barcelona Clinic Liver Cancer (BCLC) staging system, 3, 4 the National Comprehensive
Cancer Network (NCCN) guideline, a major pillar of oncologic practice, recommends radiotherapy as a preferred option. 5 Radiotherapy has recently gained popularity because of substantial local antitumor effects. 6 In particular, stereotactic body radiotherapy (SBRT) has become an important option for selected patients ineligible for RFA or TACE who have unresectable hepatic lesions measuring <5 cm and good liver function. 7, 8 Accumulating evidence indicates that SBRT may be effective for hepatic tumors, with a satisfactory local control rate and tolerable toxicity profiles in both retrospective [9] [10] [11] [12] [13] [14] [15] [16] and prospective [17] [18] [19] [20] settings. Recently, local control rates of 80-100% have been demonstrated with SBRT using volumetric modulated arc therapy (VMAT) or Cyberknife. 11, 12, 14, 16, 19 Our institution is the first to study SBRT using helical tomotherapy (HT) for hepatic tumors and has achieved good response rates since 2006.
SBRT utilizes sophisticated treatment planning, special patient immobilization devices, and precise image guidance to deliver high radiation doses to tumors in 1-5 fractions. SBRT can be performed using 3-dimensional conformal radiotherapy techniques (3D-CRTs) or intensity modulated radiation therapy (IMRT) with VMAT, HT, or Cyberknife. Each modality has been studied regarding SBRT competence and is considered effective, with strengths and weaknesses. Many studies compared performances of various SBRT modalities from clinical and dosimetric viewpoints. 21, 22 However, such comparison studies have been limited in HCC. In current HCC clinical practice, SBRT is mainly used as salvage treatment after RFA or TACE failure, rather than primary treatment; HCC-specific clinical consideration is thus required.
Our institution makes available several precise radiotherapy systems, including HT, VMAT, and Cyberknife. Although these modalities have been proven effective for liver tumor SBRT, there is a growing need to select optimal modalities depending on clinical situations. Herein, we aimed to provide a practical guideline regarding the optimal modality in a certain situation retrospectively based on our experiences with dosimetric parameters, clinical applications, and patient compliance.
METHODS

Patient data
Thirty-nine patients with primary HCC treated via liver SBRT in our institution between July 2014 and July 2015 were selected as follows: HT SBRT, 22 patients (T group); VMAT SBRT, 13 (V group); Cyberknife SBRT, 4 patients (C group).
Patients' characteristics are shown in Table 1 .
All patients had Child-Pugh scores of A or B (≤7). Only 1 patient had lung metastasis; no others had extrahepatic metastasis. All but 1 patient had no vascular tumor thrombosis.
Most patients (n=37, 95%) received other treatment before SBRT and were referred to our department for salvage treatment even after several treatment sessions. Twenty T group patients who received initial curative radiotherapy for newly diagnosed HCC experienced TACE or TACI failure. Twelve V group patients (except 1 with postoperative S1 recurrence) received SBRT after TACE or TACI failure. At the time of SBRT, residual lipiodol was detected via cone-beam computerized tomography (CT) in 55% (n=12) of T group, 77%
(n=10) of V group, and 25% (n=1) of C group patients. Regarding tumor location, 36% (n=14) of tumors were located
[n=6, 15%]). Few tumors were located in S2 (n=1, 3%), S3
(n=2, 5%), or S6 (n=0) ( Table 2 ). (23) 3 (23) 1 (25) Alcohol-related 1 (4) 2 ( 
Treatment planning
Dosimetric evaluation parameters
Each plan PTV was compared regarding dose conformity and homogeneity. Conformity evaluation used the compo- 
Statistical analysis
The benefit for each treatment group was assessed separately. Data from all plans were compared with the non-parametric Kruskal-Wallis test and Mann-Whitney test (SPSS 15.0; SPSS Inc., Chicago, IL, USA). Statistical significance was set at a P value ≤ 0.05.
RESULTS
Target coverage, conformity, and heterogeneity
The average ITVs (GTVs in group 3) were 36.0 mL, 37.3 mL, and 43.3 mL in T group, V group, and C group, respectively. The corresponding average PTVs were 87.6 mL, 85.8 mL, and 79.0 mL, respectively. There were no statistically sig- (Table 2 ).
Organ-at-risk dose sparing
All plans achieved our institution's dose constraints for critical organs. Stomach and duodenum D 0.03cc and D 2cc and remaining normal liver D mean did not significantly differ among modalities (Table 2) . 
Patient model plan comparison
Monitor unit and delivery time
The 
Clinical benefit
Thirty-six of 39 patients had a previous TACE/TACI history involving radioopaque lipiodol deposition in the tumor area that might act as a good internal fiducial marker. For VMAT and Cyberknife, high-resolution kVCT was acquired immediately before treatment, and well-traced residual lipiodol increased the ease, speed, and accuracy of treatment setup. However, lipiodols could not be visualized or traced as an internal marker using MVCT in HT SBRT. The recurrencefree survival rates from the start date of radiotherapy were 92% and 89% at 1-year and 2-year, respectively. The overall survival rates from the start date of radiotherapy were 95%
and 80% at 1-year and 2-year, respectively. There was no radiation-toxicity until last follow-up.
Patient compliance
For each modality, we analyzed compliance with treatment time, need for hospital admission or any invasive procedure, and treatment period (Table 3) Since its development to treat intracranial malignancies, SBRT has been extended to treat extracranial malignancies.
SBRT for liver tumors was introduced in the early 1990s. Currently, SBRT is indicated as a second or salvage option when other options, including TACE and RFA, are not applicable, rather than a first option. 7, 8 In our study, all but 2 patients received salvage SBRT after other treatments failed. 
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